Takuro Okada1, Isaku Okamoto2, Hiroki Sato1, Tatsuya Ito1, Keitaro Miyake1, Kiyoaki Tsukahara1. 1. Department of Otorhinolaryngology and Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan. 2. Department of Otorhinolaryngology and Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan isaku@tokyo-med.ac.jp.
Abstract
BACKGROUND/AIM: For recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), popular regimens containing platinum-based anticancer agents and immune checkpoint inhibitors are impractical for platinum-intolerant patients. Herein, the efficacy and safety of paclitaxel and cetuximab combination therapy in R/M SCCHN were evaluated. PATIENTS AND METHODS: In this retrospective study, paclitaxel (80 mg/m2) and cetuximab (400 mg/m2 loading dose followed by 250 mg/m2 weekly) were administered in 28-day cycles on days 1, 8, and 15. RESULTS: Thirty-eight patients were treated. The overall response and disease control rates of first-line therapy were 43% and 79%, respectively, while those of second-line and later therapies were 20% and 90%, respectively. The median progression-free and overall survival were 5.3 and 12.5 months, respectively. All adverse events were manageable, including grade 3/4 neutropenia and anaemia affecting 8-13% of patients. CONCLUSION: Paclitaxel and cetuximab combination therapy may be suitable for treating R/M SCCHN. Copyright
BACKGROUND/AIM: For recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), popular regimens containing platinum-based anticancer agents and immune checkpoint inhibitors are impractical for platinum-intolerant patients. Herein, the efficacy and safety of paclitaxel and cetuximab combination therapy in R/M SCCHN were evaluated. PATIENTS AND METHODS: In this retrospective study, paclitaxel (80 mg/m2) and cetuximab (400 mg/m2 loading dose followed by 250 mg/m2 weekly) were administered in 28-day cycles on days 1, 8, and 15. RESULTS: Thirty-eight patients were treated. The overall response and disease control rates of first-line therapy were 43% and 79%, respectively, while those of second-line and later therapies were 20% and 90%, respectively. The median progression-free and overall survival were 5.3 and 12.5 months, respectively. All adverse events were manageable, including grade 3/4 neutropenia and anaemia affecting 8-13% of patients. CONCLUSION:Paclitaxel and cetuximab combination therapy may be suitable for treating R/M SCCHN. Copyright
Authors: X León; R Hitt; M Constenla; A Rocca; R Stupp; A F Kovács; N Amellal; E H Bessa; J Bourhis Journal: Clin Oncol (R Coll Radiol) Date: 2005-09 Impact factor: 4.126
Authors: Aaron E Sosa; Juan J Grau; Luis Feliz; Verónica Pereira; Diego Alcaraz; Carmen Muñoz-García; Miguel Caballero Journal: Eur Arch Otorhinolaryngol Date: 2013-05-04 Impact factor: 2.503
Authors: Barbara Burtness; Kevin J Harrington; Richard Greil; Denis Soulières; Makoto Tahara; Gilberto de Castro; Amanda Psyrri; Neus Basté; Prakash Neupane; Åse Bratland; Thorsten Fuereder; Brett G M Hughes; Ricard Mesía; Nuttapong Ngamphaiboon; Tamara Rordorf; Wan Zamaniah Wan Ishak; Ruey-Long Hong; René González Mendoza; Ananya Roy; Yayan Zhang; Burak Gumuscu; Jonathan D Cheng; Fan Jin; Danny Rischin Journal: Lancet Date: 2019-11-01 Impact factor: 79.321
Authors: Glaucia Maria de Mendonça Fernandes; Vilson Serafim Junior; Ana Lívia Silva Galbiatti-Dias; Leticia Antunes Muniz Ferreira; Márcia Maria Urbanin Castanhole-Nunes; Rosa Sayoko Kawasaki-Oyama; José Victor Maniglia; Erika Cristina Pavarino; Eny Maria Goloni-Bertollo Journal: Am J Cancer Res Date: 2022-09-15 Impact factor: 5.942